Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

ArrowMark Partners

Investor type Private Equity Firm

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 55
Average round size
info
The average size of a deal this fund participated in
$110M
Portfolio companies 43
Rounds per year 3.67
Lead investments 5
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.22
Exits 20
Key employees 2
Stages of investment
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Therapeutics
  • Medical
Summary

ArrowMark Partners is the famous VC, which was founded in 2007. The fund was located in North America if to be more exact in United States. The main office of represented VC is situated in the Denver.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Moderna Therapeutics, Twilio, Orchard Therapeutics. Among the most successful fund investment fields, there are SMS, Medical. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 4 of the founder, the chance for it to get the investment is meager. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.

The usual things for fund are deals in the range of 50 - 100 millions dollars. The fund is generally included in 2-6 deals every year. Considering the real fund results, this VC is 6 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this ArrowMark Partners performs on 6 percentage points more the average number of lead investments. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The top amount of exits for fund were in 2018. The typical startup value when the investment from ArrowMark Partners is more than 1 billion dollars.

We also calculated 2 valuable employees in our database.

The standard case for the fund is to invest in rounds with 8-9 partakers. Despite the ArrowMark Partners, startups are often financed by F-Prime Capital, New Enterprise Associates, Pfizer Venture Investments. The meaningful sponsors for the fund in investment in the same round are Perceptive Advisors, RA Capital Management, OrbiMed. In the next rounds fund is usually obtained by The Durst Organization Inc., Elysium Capital Management, Stratim Capital.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of ArrowMark Partners:
Typical Co-investors
ArrowMark Partners is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after ArrowMark Partners:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Sonendo

Biotechnology
Health Care
Medical
$63M23 Sep 2022 California, United States

Dren Bio

Biotechnology
Health Care
Life Science
$65M14 Jun 2022 California, United States

Beta Bionics

Biotechnology
Diabetes
Medical Device
$57M17 Feb 2022 Boston, Massachusetts, United States

Simcha Therapeutics

Biotechnology
Life Science
Pharmaceutical
Therapeutics
$40M27 Jan 2022 New Haven, Connecticut, United States

Big Health

Fitness
Health Care
Medical
Wellness
$75M19 Jan 2022 San Francisco, California, United States

Fyllo

Cannabis
Cloud Computing
Cloud Data Services
Compliance
Enterprise Software
Software
$40M08 Nov 2021 Chicago, Illinois, United States

SmartLabs

Biotechnology
Life Science
Manufacturing
Pharmaceutical
$250M20 Sep 2021 Boston, Massachusetts, United States

Ginkgo Bioworks

Biopharma
Biotechnology
Chemical
$775M17 Sep 2021 Boston, Massachusetts, United States

Frontier Medicines

Artificial Intelligence
Biotechnology
Pharmaceutical
$88M19 Jul 2021 San Francisco, California, United States
News
SmartLabs Announces $250 Million Series B and Update of Proprietary Laboratory OS

– SmartLabs, a Boston-based Laboratory-as-a-Service (LaaS) leader, announced the raise of a $250m Series B financing.
– The funding round was led by ArrowMark Partners. New investment partners include Winslow Capital Management and Onex Falcon, joined by existing investors Conversion Venture Capital (CVC2) and Breed’s Hill Capital.
– The funding will fuel the company’s accelerated growth, with a plan to scale operations to 2m sq ft within five years.
– In addition, SmartLabs announced the launch of the fourth version of its proprietary laboratory operations system (SmartLabs OS) which was first pioneered and introduced in 2016.

Tvardi Therapeutics Raises $74M in Series B Financing

– Tvardi Therapeutics, Inc. from Houston, Texas is a clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors.
– The company closed a $74m Series B funding.
– The round was led by new investors Slate Path Capital, Palkon Capital, ArrowMark Partners, and 683 Capital with participation from existing investors including Sporos Bioventures.
– The new investment will be aimed at advancing its product candidates through multiple clinical data readouts in mid-stage trials for cancer and fibrosis.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent ArrowMark Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: